ATE122237T1 - Hiv-1 neutralisierende monoklonale antikörper. - Google Patents

Hiv-1 neutralisierende monoklonale antikörper.

Info

Publication number
ATE122237T1
ATE122237T1 AT88906589T AT88906589T ATE122237T1 AT E122237 T1 ATE122237 T1 AT E122237T1 AT 88906589 T AT88906589 T AT 88906589T AT 88906589 T AT88906589 T AT 88906589T AT E122237 T1 ATE122237 T1 AT E122237T1
Authority
AT
Austria
Prior art keywords
hiv
antibodies
monoclonal antibodies
neutralizing monoclonal
disclosed
Prior art date
Application number
AT88906589T
Other languages
English (en)
Inventor
Tse Wen Chang
Sek C Fung
Cecily Rou-Yun Sun
Bill Nai-Chau Sun
Nancy T Chang
Ruey Shyan Liou
Edward M Rosen
Original Assignee
Tanox Biosystems Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Biosystems Inc, Baylor College Medicine filed Critical Tanox Biosystems Inc
Application granted granted Critical
Publication of ATE122237T1 publication Critical patent/ATE122237T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT88906589T 1987-05-29 1988-05-27 Hiv-1 neutralisierende monoklonale antikörper. ATE122237T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5744587A 1987-05-29 1987-05-29
US13786187A 1987-12-27 1987-12-27
US19776688A 1988-05-23 1988-05-23

Publications (1)

Publication Number Publication Date
ATE122237T1 true ATE122237T1 (de) 1995-05-15

Family

ID=27369250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88906589T ATE122237T1 (de) 1987-05-29 1988-05-27 Hiv-1 neutralisierende monoklonale antikörper.

Country Status (6)

Country Link
EP (1) EP0366718B1 (de)
JP (1) JP2520464B2 (de)
AT (1) ATE122237T1 (de)
CA (1) CA1339857C (de)
DE (1) DE3853779T2 (de)
WO (1) WO1988009181A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854400A (en) * 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US5591829A (en) * 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
ATE138077T1 (de) * 1988-01-26 1996-06-15 Us Health Synthetisches antigen zum bewirken einer anti-hiv-reaktion
JP2646007B2 (ja) * 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
EP0339504A3 (de) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
DE68926813T2 (de) * 1988-05-13 1997-07-17 Competitive Tech Inc Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
AU640619B2 (en) * 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
EP0365209A3 (de) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Aminosäuresequenz des Anti-leu 3a
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
DE69029937T2 (de) * 1989-04-25 1997-05-28 Tanox Biosystems Inc FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
JP2782232B2 (ja) * 1989-05-29 1998-07-30 日東電工株式会社 プロテアーゼ阻害剤
AU6036690A (en) * 1989-06-05 1991-01-07 Helen F. Carson Human monoclonal antibodies to hiv-1mn gp 120
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
CA1339415C (en) * 1989-08-24 1997-09-02 Milton David Goldenberg Detection and treatment of infections with immunoconjugates
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
WO1991007493A1 (en) * 1989-11-13 1991-05-30 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
WO1991007494A1 (en) * 1989-11-13 1991-05-30 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
ATE143377T1 (de) * 1989-12-27 1996-10-15 Centocor Inc Schimäre immunoglobuline für cd4-rezeptoren
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
SE9000333D0 (sv) * 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
US5914109A (en) * 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
JP2989862B2 (ja) * 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
US5712373A (en) * 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
WO1992005799A1 (en) * 1990-09-28 1992-04-16 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
CA2094713A1 (en) * 1990-10-26 1992-04-27 Shermaine A. Tilley Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
AU8900691A (en) * 1990-11-19 1992-06-11 Queen's University At Kingston Hiv marker/aids vaccine
CA2094611C (en) * 1991-08-22 2000-07-25 Tsuneya Ohno Hiv immunotherapeutics
WO1994004574A1 (en) * 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
JPH0748276A (ja) * 1992-03-26 1995-02-21 Inmeru:Kk Ｈｉｖ感染症予防ワクチンおよびその製造法
CZ239694A3 (en) * 1992-04-01 1995-07-12 Merck & Co Inc Recombinant human antibody against hiv, cassette for expression, host cell and a pharmaceutical preparation against hiv
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
KR100337069B1 (ko) * 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
AU6518698A (en) * 1997-03-28 1998-10-22 Seikagaku Corporation Novel anti-hiv complexes and medicinal compositions
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
US6472191B1 (en) 1998-12-03 2002-10-29 Canon Kabushiki Kaisha Dna fragment carrying toluene monooxygenase gene, recombinant plasmid, transformed microorganism, method for degrading chlorinated aliphatic hydrocarbon compounds and aromatic compounds, and method for environmental remediation
EP2016173A4 (de) * 2006-05-15 2010-06-09 Immunomedics Inc Verfahren und zusammensetzungen zur behandlung menschlicher immundefekt-virusinfektionen mit konjugierten antikörpern oder antikörperfragmenten
WO2016191481A1 (en) 2015-05-28 2016-12-01 Immunomedics, Inc. T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2571968B1 (fr) * 1984-10-18 1989-03-17 Pasteur Institut Virus purifie des lymphadenopathies et du syndrome d'immuno-depression acquise et antigenes d'enveloppe de ce virus, procede d'obtention de ce virus et de ces antigenes d'enveloppe de ce virus, applications de ce virus ou de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic des susdites affections.
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0387914B1 (de) * 1984-10-18 1993-08-04 Institut Pasteur Hüllenantigene vom menschlichen Immunodefizienz-Virus und deren Verwendungen
JP2702911B2 (ja) * 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法
EP0245362B1 (de) * 1985-10-24 1994-06-29 Ronald C. Kennedy Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections

Also Published As

Publication number Publication date
JPH03504556A (ja) 1991-10-09
DE3853779T2 (de) 1995-09-07
EP0366718A1 (de) 1990-05-09
EP0366718B1 (de) 1995-05-10
WO1988009181A2 (en) 1988-12-01
DE3853779D1 (de) 1995-06-14
WO1988009181A3 (en) 1989-02-09
JP2520464B2 (ja) 1996-07-31
CA1339857C (en) 1998-05-05

Similar Documents

Publication Publication Date Title
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
DE3850542T2 (de) Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
EP0651818A4 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung.
IL91007A0 (en) Synthetic vaccine against aids virus
ES2194015T3 (es) Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
IL118626A0 (en) Anti HBV antibody
SE8703225D0 (sv) Monoclonal antibodies and peptides useful in treating and diagnosing hiv infections
ATE238420T1 (de) Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DE69227500T2 (de) In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper
WO1997046697A3 (en) Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
EP0306219A3 (de) HIV-Proteine und Peptide zur Verwendung in Diagnose, Prophylaxe und Therapie von AIDS
ES468363A1 (es) Proceso para la fabricacion de un preparado destinado al tra-tamiento de herpes-zoster.
AU8010791A (en) Hiv monoclonal antibody
DE3854267D1 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
WO1993001820A3 (en) Inhibition of non-cd4 mediated hiv infection
ATE80553T1 (de) Behandlung von viraler infektion.
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
AU660916B2 (en) Beta-hydroxamate D-aspartic acid for treatment of viral infections and tumours
DE69619123D1 (de) Hämoregulatorische verbindungen
EP0835124A4 (de) Serumzusammensetzungen zur hemmung von retroviren und tumorwachstum
RU94024562A (ru) Антитело, полинуклеотид, клетка, способ получения антитела

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee